TRCT
OKUR

Tower Research Capital (TRC)’s OnKure Therapeutics OKUR Stock Holding History

Tower Research Capital (TRC)’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,935
Closed -$5.32K – 5717
2025
Q3 		$5.32K Buy
1,935
+103
+6% +$255 ﹤0.01% 4245
2025
Q2 		$4.38K Sell
1,832
-392
-18% -$1.03K ﹤0.01% 4336
2025
Q1 		$9.56K Buy
2,224
+23
+1% +$129 ﹤0.01% 3758
2024
Q4 		$18.9K Buy
2,201
+170
+8% +$2.57K ﹤0.01% 3227
2024
Q3 		$34.5K Buy
2,031
+537
+36% +$7.94K ﹤0.01% 2931
2024
Q2 		$22.6K Buy
1,494
+546
+58% +$9.26K ﹤0.01% 3684
2024
Q1 		$15.7K Buy
948
+270
+40% +$4.46K ﹤0.01% 3228
2023
Q4 		$10.8K Buy
678
+530
+358% +$33K ﹤0.01% 4197
2023
Q3 		$11.3K Buy
148
+74
+100% +$5.03K ﹤0.01% 4011
2023
Q2 		$4.85K Sell
74
-174
-70% -$14K ﹤0.01% 4894
2023
Q1 		$15K Sell
248
-344
-58% -$12.5K ﹤0.01% 3834
2022
Q4 		$14K Buy
+592
New +$15.7K ﹤0.01% 3548
2022
Q3 		– Sell
-129
Closed -$3K – 6570
2022
Q2 		$3K Sell
129
-851
-87% -$19.8K ﹤0.01% 5425
2022
Q1 		$29K Buy
980
+856
+690% +$47.9K ﹤0.01% 3204
2021
Q4 		$11K Sell
124
-6
-5% -$441 ﹤0.01% 4472
2021
Q3 		$10K Buy
130
+126
+3,150% +$10.7K ﹤0.01% 4350
2021
Q2 		$0 Buy
+4
New +$446 ﹤0.01% 5912

Other funds holding OKUR

ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Tower Research Capital (TRC)'s OKUR Position: Q4 2025 in Review

Tower Research Capital (TRC) sold out of OnKure Therapeutics (OKUR) in Q4 2025, closing a stake of 1,935 shares — an estimated $5.32K sold.

Tower Research Capital (TRC) first reported a position in OKUR in Q2 2021 and held it in 17 quarters. The position peaked at $34.5K in Q3 2024. 44 funds tracked by Wall St. Rank hold OKUR as of Q4 2025.

  • Tower Research Capital (TRC) reported no remaining OnKure Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 1,935 OnKure Therapeutics shares in Q4 2025, an estimated $5.32K.
  • Tower Research Capital (TRC) first reported a position in OnKure Therapeutics in Q2 2021 and held it in 17 quarters.
  • Tower Research Capital (TRC)'s OnKure Therapeutics position peaked at $34.5K in Q3 2024.
  • 44 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q4 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2025, filed 17 Feb 2026.